Last quarter (Q3 2023), Viracta Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q3, Viracta Therapeutics's net income was $-12.60M. See Viracta Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21
Total Revenue	-	-	-
Cost of Revenue	-	-	-
Gross Profit	-	-	-
Operating Expense	$ 25.56M	$ 50.59M	$ 114.28M
Operating Income	$ -48.71M	$ -50.59M	$ -114.28M
Net Non Operating Interest Income Expense	$ 288.00K	$ 594.00K	$ -453.00K
Other Income Expense	$ -932.00K	$ -620.00K	$ 33.00K
Pretax Income	$ -47.49M	$ -49.38M	$ -114.76M
Tax Provision	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-
Net Income Common Stockholders	$ -47.51M	$ -49.38M	$ -114.76M
Basic EPS	$ -1.52	$ -1.30	$ -3.60
Diluted EPS	$ -1.99	$ -1.30	$ -3.60
Basic Average Shares	$ 153.49M	$ 37.79M	$ 31.87M
Diluted Average Shares	$ 153.49M	$ 37.79M	$ 31.87M
Dividend Per Share	-	-	-
Total Operating Income As Reported	-	-	-
Reported Normalized Basic E P S	-	-	-
Reported Normalized Diluted E P S	-	-	-
Rent Expense Supplemental	-	-	-
Total Expenses	$ 25.56M	$ 50.59M	$ 114.28M
Net Income From Continuing And Discontinued Operation	$ -47.60M	$ -49.20M	$ -114.76M
Normalized Income	$ -9.88M	$ -39.01M	-
Interest Expense	-	-	-
EBIT	$ -48.02M	$ -48.80M	$ -114.31M
EBITDA	$ -49.23M	$ -49.21M	$ -114.13M

Currency in USD

Viracta Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing